Abstracts A19 (OR:1.16; CI:1.03-1.31), and 2 (OR:1.47; CI:1.30-1.65)]. Findings were similar when stratifying the sample by age group. CONCLUSIONS: Findings suggest that a quarterly assessment of SABA utilization can be used to identify patients at risk for asthma-related exacerbations. The incidence of an asthma exacerbation was associated with greater SABA use in the previous quarter. OBJECTIVES: Comorbidities in patients with chronic obstructive pulmonary disease (COPD) are associated with higher mortality, hospitalization, and poor quality of life. The objectives of this study were to characterize a comprehensive comorbidity profi le among COPD patients, and to explore the impact of comorbidities on medical utilization and cost in a low-income Medicaid population. METHODS: This retrospective cohort study analyzed medical claims from the Maryland Medicaid database. We employed a 1:2 case-control design to select 1388 COPD patients aged 40 to 64 years with at least 24 months of continuous enrollment and 2776 demographically-matched controls without COPD. Logistic regressions were performed to calculate odds ratios that compared differences in the prevalence of comorbidities, including 17 conditions defi ned by the Charlson Comorbidity Index (CCI) and 6 additional conditions known to coexist with COPD. Generalized linear models were performed to estimate the average medical utilization and cost by specifi c comorbidity. RESULTS: Medicaid COPD patients had more comorbidities compared with non-COPD controls (CCI score 1.56 vs. 1.37, p 0.004), and were more likely to have myocardial infarction, congestive heart failure, cerebrovascular disease, peptic ulcer, mild liver disease, hypertension, sleep apnea, tobacco use, and edema. COPD patients on average had 16 more medical claims (81.4 vs. 65.4, p 0.001) and incurred $1871 higher medical cost per year than non-COPD controls ($7603 vs. $5732, p 0.001). Ten out of the 17 conditions defi ned by the CCI as well as hypertension, tobacco use, and edema were associated with the excess medical utilization and cost in COPD patients. Depression was associated with excess medical utilization but not cost. CONCLUSIONS: Medicaid COPD patients have a substantial burden of comorbidities, which translate into higher medical utilization and cost. Effective disease management and treatment protocols are needed to reduce co-morbidity burden. OBJECTIVES: To assess real-world effectiveness of BUD/FM DPI versus tiotropium DPI in COPD patients METHODS: Data from the Quebec health care databases were used to construct a matched cohort of COPD patients aged d40 years newly treated with BUD/FM DPI or tiotropium DPI from 2003-2007. Patients were matched on age, sex, COPD exacerbations (short-course prescription of oral corticosteroids [OCSs], emergency department [ED] visits or hospitalizations for COPD; d2 events occurring within 15 days counted as 1 exacerbation), and use of short-acting inhaled ]2-agonists (SABAs) and ipratropium in the year before therapy began. The number of exacerbations, ED visits, and hospitalizations for COPD; claims for OCS prescriptions; and the average weekly doses (dose 2 inhalations) of SABAs and ipratropium were compared for BUD/FM DPI versus tiotropium DPI users for a 1-year post-therapy period. Poisson and linear regression models were used to produce adjusted rate ratios (RR) and mean differences (MD). RESULTS: Of 981 BUD/FM DPI and 981 tiotropium DPI users in the cohort, 78% were aged "d 65 years and 53% were men. No signifi cant differences were seen for COPD exacerbations (RR 0.94; 95% CI, 0.77-1.15), ED visits for COPD (RR 0.80; 95% CI, 0.54-1.20), and claims for OCS prescriptions (RR 0.93; 95% CI, 0.72-1.21) between BUD/FM DPI and tiotropium DPI users in the year after the start of therapy. However, BUD/FM DPI users had signifi cantly fewer hospitalizations for COPD (RR 0.65; 95% CI, 0.44-0.97), used less SABAs (MD 0.48; 95% CI, 0.67 to 0.28), and used more ipratropium (MD 0.35; 95% CI, 0.21-0.50). CONCLUSIONS: These fi ndings showed that patients using BUD/FM DPI were signifi cantly less likely to have COPD exacerbations leading to a hospitalization, but as likely as tiotropium DPI users to require emergency care or OCS therapy in the year after initiation of therapy.
RR4 OUTCOMES ASSOCIATED WITH TIOTROPIUM USE IN COPD PATIENTS
Lee TA 1 , Wilke CT 2 , Joo M 3 , Stroupe KT 4 , Krishnan JA 5 , Schumock GT 2 , Pickard AS 2 1 Hines VA Hospital and Northwestern University, Chicago, IL, USA, 2 College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA, 3 Hines VA Hospital and University of Illinois at Chicago, Chicago, IL, USA, 4 Midwest Center for Health Services & Policy Research, Hines, IL, USA, 5 University of Chicago, Chicago, IL, USA OBJECTIVES: To date, there is mixed evidence on the safety and effectiveness of tiotropium. Our objective was to evaluate the comparative effectiveness of regimens containing tiotropium versus other medication regimens for chronic obstructive pul-monary disease (COPD) in real-world clinical settings. METHODS: We conducted a cohort study on two separate cohorts with a diagnosis of COPD in the VA health care system. Patients with a COPD diagnosis prescribed tiotropium and patients in a historic cohort prior to the introduction of tiotropium were selected for comparison using propensity scores, with the base case including scores from 0.1 to 0.4. Outcomes identifi ed during follow-up were all-cause mortality, COPD exacerbations, and COPD hospitalizations. Exposure to COPD medication regimens was defi ned in a time-varying manner and Cox proportional hazards regression were employed to evaluate outcomes. RESULTS: For 42,090 patients in the base case, the regimen of tiotropium plus inhaled corticosteroids plus long-acting beta-agonists was associated with 40% reduced risk of death (HR 0.60 [95% CI 0.45, 0.79]) compared to inhaled corticosteroids plus long-acting beta-agonists. This combination was also associated with reduced rates of COPD exacerbations (HR 0.84 [0.73, 0.97] ) and COPD hospitalizations (HR 0.78 [0.62, 0.98]) . Tiotropium in combination with other medication regimens was associated with increased risk of events compared to inhaled corticosteroids plus long-acting beta-agonists. CONCLUSIONS: When used with inhaled corticosteroids and long-acting beta-agonists, tiotropium use was associated with a decreased risk of mortality compared to treatment with inhaled corticosteroids and long-acting beta-agonists. However, this result was not consistent in other medication regimens that included tiotropium.
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CONCEPTUAL PAPERS & RESEARCH ON METHODS -Clinical Outcomes Methods
PMC1 CLASSIFYING PATIENTS WITH METABOLIC SYNDROME USING THE LATENT CLASS ANALYSIS (LCA)
Liu G 1 , Luo N 2 , McCollam PL 3 1 Peking University, Beijing, China, 2 National University of Singapore, Singapore, Singapore, 3 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: To identify subgroups of metabolic syndrome patients who would be more homogeneous in terms of metabolic risk factors. METHODS: The electronic medical record database from GE Healthcare was used for this study. The database comprises de-identifi ed longitudinal medical records of nationally representative patients attending general practitioners. All adult patients were assessed for the presence of metabolic syndrome using the guidelines proposed by the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III). A latent class analysis was conducted based on the abnormality of patients' metabolic risk factors including triglycerides (TG; 150 mg/dL), high-density lipoprotein cholesterol (HDL-C; men: 40 mg/dL; women: 50 mg/dL), blood pressure (BP; systolic 130 mmHg, diastolic 85 mmHg, or drug treatment for hypertension), fasting plasma glucose ( 100 mg/dL or drug treatment for diabetes mellitus), and waist circumference (WC; men: 102 cm; women: 88 cm). The fi nal model was selected based on model fi t indices including Akaike's information criterion, Bayesian information criterion (BIC), and sample-size adjusted BIC. RESULTS: Metabolic syndrome was present in 19,251 individuals. The prevalence of high blood pressure was 96.4%. All the fi t indices in the LCA modeling pointed to a 5-class solution. In addition to high blood pressure, members of Class 1 (6.5%) had abnormal TG and HDL-C; members of Class 2 (4.6%) had abnormal HDL-C and WC; members of Class 3 (19.7%) had abnormal TG and WC and the majority also had abnormal HDL-C (probability: 68.7%); members of Class 4 (8.2%) had abnormal plasma glucose and WC; and members of Class 5 (61.1%) had high probability of abnormality in all metabolic risk factors (range: 79.9-100%). CONCLUSIONS: LCA represents a new method for casemix study of patients with metabolic syndrome. The subgroups of metabolic syndrome identifi ed in this study need to be further studied for its usefulness in clinical and health services research.
PMC2 LONGITUDINAL DATA EXPLORATION WITH STACKED CUMULATIVE PERCENT PLOTS FOR CATEGORICAL DATA
Gilligan TM g , Hill CD RTI Health Solutions, Research Triangle Park, NC, USA Longitudinal clinical trial data present analysts with the unique challenge of summarizing large trends over time without losing the detail of changes from one timepoint to the next. Analysts must fi nd a balance between the preservation of details at each timepoint and parsimonious output that can be easily summarized and interpreted. For instruments that measure outcomes using nominal or ordinal response categories, analysts may want to preserve categorical information by reporting response category frequencies over time. In this case, the frequency of change across the course of treatment or disease progression is more informative, and perhaps more appropriate, than mean or median change. Collapsing responses into mean or medians draws attention to overall trends, while losing the ability to detect movement from one category response to another. A novel data visualization solution, stacked cumulative percent plots, allows analysts to retain individual categorical responses and track the movement of categorical responses over time. Comparisons of stacked cumulative percent plots with mean plots illustrate the additional information that can be learned from retaining categorical information. Further, a variation of the proposed plot allows analysts to visualize the frequency of response category changes from timepoint to timepoint. Stacked cumulative percent plots can be applied to diverse disease types and to outcomes with varying amounts of anticipated change from timepoint to timepoint.
PMC3 USING FRONTIER ANALYSIS TO OPTIMIZE THE OVERALL LIFE YEARS GAINED IN VACCINATION POLICY OF INFECTIOUS DISEASES
Chang CJ 1 , Wu D 2 , Lin YJ 1 , Fann CS 3 1 Chang Gung University, Tao Yuan, Tao Yuan, Taiwan, 2 National Yang-Ming University, Taipei, Taiwan, 3 Academia Sinica, Taipei, Taiwan OBJECTIVES: The aim of the study is to utilize the novel frontier analysis to search for optimal strategy of vaccination policy against infectious diseases with limited vaccine supply. METHODS: An important goal of public health research is to predict clinical impact by nation-wide mass vaccination in preventing infectious diseases. Vaccination is usually given across potential vulnerable populations such as children. However, due to limited resources provided by the government among a growing number of competing vaccine products, some vaccinations are to be given to some targeted high-risk cohorts against infectious diseases, such as pneumonia or infl uenza. Hence, the optimal strategy of vaccination policy for effective disease control becomes a practical concern. We propose a model using frontier analysis to seek the optimal vaccination policy in controlling infectious disease epidemics with limited resources. The problem is initially formulated to fi nd the maximal life years gained while minimizing the variance. Various vaccination policies were explored in fi nding the optimal vaccination strategy. The indirect effects on unvaccinated cohorts were also considered in the analysis. The technique is illustrated using pneumococcal conjugate vaccine (PCV) in Taiwan as an example. RESULTS: Using the empirical study of PCV and various scenarios of the policy with limited resource, we provide the best vaccination strategy among various defi ned cohorts and report the maximal life years gained with the fi xed total cost of the vaccine given. Our study can be generalized to the optimization of vaccination strategies for most infectious diseases among different population structures. CONCLUSIONS: When disease burden is high, more emphasis should be laid on the possible health benefi ts gained with a vaccination program, instead of just considering the economic benefi ts. Our study can help to guide decision makers in determining optimal uses of limited quantities of vaccine across multiple targeted cohorts to effectively control infectious diseases.
PMC4 A FRAMEWORK FOR DEVELOPING A FLEXIBLE CONTROL-BASED ASTHMA POLICY MODEL
Campbell JD p J 1 , Hansen RN 1 , Briggs A 2 , Sullivan SD 1 1 University of Washington, Seattle, WA, USA, 2 University of Glasgow, Glasgow, UK OBJECTIVES: The goal of asthma management is to gain and maintain control. Several validated patient-reported measures are available to assess the degree of control: Asthma Control Questionnaire (ACQ), Asthma Control Test (ACT), and the Asthma Therapy and Assessment Questionnaire (ATAQ). We propose a fl exible and transparent model structure that represents disease variability through exacerbation rates and any one of the three control instruments. METHODS: We developed a Markov model to simulate cohorts transitioning among six health states: an asthma control continuum state (variability in control is tracked using one of the three control instruments), three severity levels of asthma exacerbation, and asthma and non-asthma related death. To estimate the cost and outcome weights for the control continuum state, we explored the relationship between the ATAQ (higher ATAQ less control) and management costs (including absenteeism costs) and utilities using a large asthma registry of exacerbation-free patients. A hypothetical asthma intervention added to standard-of-care was compared to standard-of-care alone as summarized by the following product profi le: a 50% reduction in asthma exacerbation rates, a 0.5 absolute improvement in the ATAQ score, and an additional $10,000 per annum intervention cost. RESULTS: The estimated change in bi-weekly asthma management costs for a one unit increase in the ATAQ score was $36.12 (robust SE $3.95) and for utilities was 0.05 (robust SE 0.0041). Assuming a fi ve year time horizon, the hypothetical intervention plus standard-of-care had an incremental mean cost of $25,800 (95% interval $10,600, $41,000), quality adjusted life year (QALY) of 0.257 (0.106, 0.435), and cost per QALY of $100,500/QALY ($13,700, $199,800) . CONCLUSIONS: As relationships emerge between any of the instruments of control and costs and utilities, this versatile model can forecast: long-term burden of disease, value of existing and emerging interventions, and inputs that yield the highest return from further study.
PMC5 PRO AND UTILITY ASSESSMENT: ADDRESSING CONFOUNDS OF CHANGING SELF-REFERENCE Pashko S
Omnicare Clinical Research, King of Prussia, PA, USA Identity, the view of self-reference, is not static across populations and is probably not stable within an individual over time. Philosophers, psychologists and the religious continue to offer support for particular points of view of identity but there are many differences among them. These differences seem quite able to bias utility and patientreported outcomes assessments. As such, care must be taken to understand the selfreference schemas of the population within which self-assessments are validated and used. Some of the options people have and use for self-reference are: 1. operational (e.g., I am a clinical researcher or a father), 2. preference-oriented (e.g., I am a lover of wine or a "runner"), 3. physical (e.g., I am my body), 4. psychological (e.g., I am my ego), 5. religious (e.g., I am spirit) and 6. philosophical (e.g., I am thinking, I am consciousness, no such thing as identity exists, I am subjective experience). It's surprising self-assessments are conducted when we don't know who is responding to our questions. The confound of identity is important to study in its own right because of how strongly it can infl uence public policy through research fi ndings based on selfassessments. "View of self-reference" seems a fundamental and necessary element for inclusion into requirements for construction and validation of PROs. Otherwise, instrument bias could be specifi cally used to make a certain claim, much like regression towards the mean could be used if it was not previously identifi ed as a threat to validity. That identify may shift over time within an individual, say from an external focus to an internal focus, may be the reason why some terminally ill patients report good quality of life despite their poor health. When the body is not a factor in one's identity, what is the meaningfulness of health-related quality of life anyway?
PMC6
META-REGRESSION AS A METHOD OF IDENTIFICATION OF THE CAUSES OF HETEROGENEITY BETWEEN STUDIES ON THE EXAMPLE OF RELATIONSHIP BETWEEN SURROGATES AND CLINICALLY IMPORTANT ENDPOINTS IN TYPE-2 DIABETES MELLITUS
Marcisz A 1 , Rys P y 2 , Wieczorek A 1 , Plisko R 2 , Wladysiuk M 1 , Skrzekowska-Baran I 3 1 HTA Consulting, Krakow, Malopolska, Poland, 2 HTA Consulting, Krakow, Poland, 3 Novo Nordisk, Inc., Warsaw, Mazowieckie, Poland OBJECTIVES: Use of meta-regression to explain heterogeneity between the studies evaluating relationship between the level of glycated hemoglobin (HbA1c) and the risk of development of retinopathy in patients with type 2 diabetes mellitus (DMT2). In meta-regression the results of the studies under consideration are treated as points to be analyzed by weighted regression. If the results obtained in a model without covariates indicate heterogeneity of studies, then inclusion of subsequent covariates into the model can make it possible to check if specifi c variables explain heterogeneity. The amount of heterogeneity may be expressed as between-study variance. If betweenstudy variance decreases after inclusion of a specifi c covariate into the model, it means that heterogeneity between the studies may be explained by that covariate. METHODS:
The following covariates were considered: observation period, type of the study, sample size, HbA1c level, age, duration of DMT2, BMI, cholesterol level, arterial blood pressure. Due to a scarce number of studies available between-study variance was estimated using the REML method. The value of between-study variance evaluated using a meta-regression model for retinopathy in DMT2 without covariates was 0.4547. RESULTS: Inclusion of the difference between the intervention group and the control group with respect to the HbA1c level resulted in decrease to 0.1572. Therefore the covariate under consideration explains the heterogeneity in 65.4%. The obtained value of directional coeffi cient was statistically signifi cant and equal to 0.5824, which means that increase of difference between the groups with HbA1c level by 1 unit results in increase of the logarithm of relative risk by 0.5824, refl ecting increase the risk by 1.79 times. CONCLUSIONS: It was demonstrated using metaregression that the difference with respect to the HbA1c level is the cause of heterogeneity between the studies. Relative risk of development of retinopathy increases with increase of the difference in HbA1c level.
PMC7
EFFECTS OF HETEROGENEITY ON THE ESTIMATION AND COMPARISON OF MEDICATION ERROR RATES
de Moor C, Golembesky A PPD Inc, Morrisville, NC, USA OBJECTIVES: The clinical consequences and costs of medication errors (ME) have signifi cant implications on quality of care. A detailed understanding of the occurrence and patterns of MEs is critical to reducing ME rates and improving patient outcomes. However, ME rates are often estimated inaccurately. ME rates are typically heterogeneous with respect to hospitals and units within hospitals, because of differences in health care provider (HCP) experience and skill. Although this heterogeneity has important implications for the precision and power of ME analysis, it is seldom taken into account in the estimation of MEs. METHODS: To evaluate the effects of heterogeneity on the precision and power of estimated ME rates, we assumed three sources of heterogeneity: hospital, unit (or HCP) within hospital, and random error. We derived formulas representing the variances of the estimated ME rates and the variances of comparisons of ME rates, and graphically illustrated the effects of sample sizes and magnitude of heterogeneity on the variances. RESULTS: The heterogeneity associated with hospital and unit induces clustering of MEs within hospitals and units, increasing variability in the estimated ME rates compared with what would be observed in the absence of heterogeneity. Even in the presence of low levels of heterogeneity, the variances of the estimated ME rates can be substantially increased. Power associated with comparisons of ME rates also can be substantially affected with decreased power for comparisons between hospitals or units and increased power for comparisons within hospitals or units. CONCLUSIONS: Heterogeneity of MEs with respect to hospitals and hospital units (or HCPs) can have a substantial effect on precision and power, and should be incorporated in the analyses ME rates. We provide precision and power formulas for planning future studies of MEs.
